灵麦医药的公司使命之一是“向中国市场引进创新医疗产品来提高中国患者的生活质量，拯救患者的生命”。为实现这个使命，灵麦医药致力于支持中国区大型医药企业引进创新医疗产品。本月，灵麦医药为您独家推荐Bio-Europe春季盛会。
本期月刊灵麦医药和您分享：
Bio-Europe春季盛会介绍
灵麦项目推荐
2018年1月博谷数据分析团队对全球新药研发行业融资情况的分析
PART I Bio-Europe春季盛会介绍
新春佳节将至，灵麦医药在此恭祝大家新春快乐。感谢各位又伴随灵麦医成长一岁。也希望各位客户在年的一年里心想事成，一帆风顺。
找项目的客户可不要错过。开春第一件大事就是3月12日-3月14日在荷兰阿姆斯特丹举办的欧洲新药高峰论坛Bio-Europe Spring. 作为欧洲最大的新药盛会，Bio-Europe不管从参会人员还是项目的数量和质量上，都是其他任何展会所无法比拟的。去年春季盛会一共吸引了1425家来自54个国家的公司，超过2521位参会人员，其中74%都是顶层或高级管理层，让您无障碍对接。3255个项目转让机会， 15028次一对一会议，，让人应接不暇。还愁找不到合适的项目？
表1：2018欧洲新药高峰论坛Bio-Europe Spring项目按研发阶段总结
表2：2018欧洲新药高峰论坛Bio-Europe Spring项目按治疗领域总结
PART II 灵麦项目推荐
项目一：移植物抗宿主病项目推荐
LMP1031项目背景
LMC500018公司开发的免疫类药品LMP1031，现在正在欧洲进行针对移植物抗宿主病( graft-versus-host disease，GVHD)的临床1/2期实验。LMC500018公司已授权灵麦医药为中国独家项目对接服务机构，如需项目接洽如对该项目感兴趣或需要更详细的项目非保密资料，请联系我们info@lingmed.net或登录
项目二：肝脏代谢领域项目推荐
公司及项目背景
LMC5000478公司是一家专注肝脏疾病细胞疗法研发的公司。该公司提供多功能和独特的细胞治疗技术，针对三个治疗领域：免疫调节，酶/缺失因子置换和细胞/组织再生。LMC5000478公司目前的重点主要是利用免疫调节在适应症治疗中提供真正差异化的治疗方案。目前该公司开发的细胞疗法产品有LMP1103，LMP1104和LMP1105。
PART III 博谷数据分析团队对全球新药研发行业融资情况的分析
2017年12月，美国和欧洲市场融资总额和11月类似，持续低迷。不过，我们还是看到了欧洲市场的一些增长，12月欧洲市场融资总额为2.56亿美元，相比11月增长了115%。同时，欧洲市场融资轮数也增加了20%(达到12轮）。但是美国市场的表现则不尽人意。相较11月下降了22%，从11月的8.25亿美元下降到12月的6.42亿美元。同样，美国融资轮数也下降了35%，（从11月的35轮下降为23轮）。 与去年同期比较，今年美国总融资金额还是有一定幅度的增长（+33%），总融资轮数也增长了35%。
今年12月，最大的一轮融资来自于上海复宏汉霖生物技术有限公司1.92亿美元的融资。该公司总部位于中国，以抗体药物研发为主，着重于研究恶性肿瘤和自身免疫疾病的生物类似药和biobetters（单克隆抗体和重组蛋白）。欲知更多2017年12月医药行业融资亮点，请阅读以下报告。
下载本期灵麦月刊或更多项目分析报告及行业洞见，请登录www.lingmed.net/reports
One of Lingmed company missions is “Bring Innovative healthcare products to China market to improve Chinese patients’ life quality and save lives.” In order to achieve this mission, currently Lingmed support big Pharma in China to identify good innovative assets to bridge the innovation into China market. This month Lingmed analyst team shares with you Bio-Europe Spring.
MONTHLY HIGHLIGHTS：
Introduction of Bio-Europe Spring
Assets recommendation
The January Financial analysis of global bio-pharmaceuticals market by Biotechgate data analysis team
PART I Bio-Europe Spring Intro
The global life science community will meet at BIO-Europe Spring® 2018 in Amsterdam, March 12-14.
BIO-EUROPE SPRING® attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts.
Over 2,600 attendees, 74% top/senior management, 15,000+ one-to-one meetings, 3,500+ licensing opportunities posted, 1,500+ companies, 120+ company presentations, 65 exhibitors, 50+ countries represented, 20+ workshops and panels.
PART II Assets recommendation
Project 1:
Immune drug - LMP1031 was developed by the company LMC500018. This product is undergoing the 1/2 clinical trial in Europe, aiming at graft-versus-host disease (GVHD).
Project 2:
Company LMC5000478 focus on reserach for cell therapy of liver cancer. This company provides multifunction and unique cell therapy technology, which mainly focus on three therapy fields: immunoregulation, enzyme/missing factor replacement and cell/tissue regeneration. Currently, this company mainly focus on providing effective differentiation therapy solutions by immunoregulation in terms of indication therapy. The products launched by this company includes LMP1103，LMP1104 and LMP1105.
PART III Biotech Financing Summary
The Financial analysis of global bio-pharmaceuticals market by Biotechgate data analysis team
After a relatively low aggregate finance amount reported in November 2017, similar trends were witnessed in December 2017. Notably, Biotech companies from Europe were able to raise a total of USD 256m, representing a 115% increase compared to November 2017. Accordingly, the number of EU financing rounds increased by 20% (up to 12 rounds). The total financing amount in the US dropped 22% from USD 825min November to USD 642m in December. The number of rounds also decreased by 35% (35 vs. 23 rounds in November and December, respectively). In comparison to December 2016, the financing volume in the US was much higher (+33%) and the number of financing rounds increased by +35%.
The largest financing round in December 2017 was demonstrated by Shanghai Henlius Biotech, Inc. with a total amount of USD 192.5m. This company, based in China, develops antibody-based therapeutics with a special focus on biosimilars and biobetters (mAbs and recombinant proteins) for malignant tumors and auto-immune diseases.
Download the whole report or more analytical reports, please visit www.lingmed.net/reports
灵麦医药是以下两家情报数据库在中国的独家合作伙伴：
Biotechgate/博谷 - 全球创新药和器械产品收购和引进数据库
EvaluatePharma/预估医药 - 全球医药研发、销售、市场预估等竞争情报数据库
想要下载完整报告?
请登录 www.lingmed.net/reports
或点击下方“阅读原文”马上下载
